Atlas Trials

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Clinical trial NCT05663866 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05663866
Sponsor
Janssen Research & Development, LLC
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Carcinoma, Non-Small-Cell Lung
Start date
2023-05-18
Primary completion
2024-03-29
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.